In contrast to our observed increase in CD16 expression in stage IV IBC, a previous report showed decreased expression of activating NK cell receptors, including CD16, during progression of non-IBC, while inhibitory receptors increased and this correlated with decreased NK cell function, at least partially due to TGF-β1 in the TME [41]. The gene discussed is FCGR3A; the disease is inflammatory breast carcinoma.